BiotechTube

DYNE-251 + Placebo

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy (DMD)

Conditions

Duchenne Muscular Dystrophy (DMD)

Trial Timeline

Aug 12, 2022 → Nov 1, 2029

NCT ID
NCT05524883

About DYNE-251 + Placebo

DYNE-251 + Placebo is a phase 1/2 stage product being developed by Dyne Therapeutics for Duchenne Muscular Dystrophy (DMD). The current trial status is active. This product is registered under clinical trial identifier NCT05524883. Target conditions include Duchenne Muscular Dystrophy (DMD).

What happened to similar drugs?

2 of 20 similar drugs in Duchenne Muscular Dystrophy (DMD) were approved

Approved (2) Terminated (8) Active (11)
❌Tadalafil + PlaceboEli LillyPhase 3
🔄Viltolarsen + PlaceboNippon ShinyakuPhase 3
🔄ViltolarsenNippon ShinyakuPhase 3
❌fordadistrogene movaparvovecPfizerPhase 3
🔄Ataluren + PlaceboPTC TherapeuticsPhase 3
🔄Ataluren + PLACEBOPTC TherapeuticsPhase 3
🔄AtalurenPTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05524883Phase 1/2Active

Competing Products

20 competing products in Duchenne Muscular Dystrophy (DMD)

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
39
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42
ViltolarsenNippon ShinyakuPhase 3
36
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
32
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
35
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
27
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
27